Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Antibiotic | Research

Etiological analysis of infection after CRS + HIPEC in patients with PMP

Authors: Rui Yang, Xin Zhao, Yu-Bin Fu, Yu-Lin Lin, Ru Ma, Yan-Dong Su, He-Liang Wu, Xin-Li Liang, Yan Li

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for pseudomyxoma peritonei (PMP). It can significantly prolong the survival of patients, but at the same time may increase the risk of postoperative infection.

Method

Patients with PMP who underwent CRS + HIPEC at our center were retrospectively analyzed. According to PMP patients, basic clinical data and relevant information of postoperative infection, we analyzed the common sites of postoperative infection, results of microbial culture and the antibiotics sensitivity. Univariate and multivariate analysis were performed to explore infection-related risk factors.

Result

Among the 482 patients with PMP, 82 (17.0%) patients were infected after CRS + HIPEC. The most common postoperative infection was central venous catheter (CVC) infection (8.1%), followed by abdominal-pelvic infection (5.2%). There were 29 kinds of microbes isolated from the culture (the most common was Staphylococcus epidermidis), including 13 kinds of Gram-positive bacteria, 12 kinds of Gram-negative bacteria, and 4 kinds of funguses. All the antibiotics sensitivity results showed that the most sensitive antibiotics were vancomycin to Gram-positive bacteria (98.4%), levofloxacin to Gram-negative bacteria (68.5%), and fluconazole to fungus (83.3%). Univariate and multivariate analysis revealed the infection independent risk factors as follow: intraoperative blood loss ≥ 350 mL (P = 0.019), ascites volume ≥ 300 mL (P = 0.008).

Conclusion

PMP patients may have increased infection risk after CRS + HIPEC, especially CVC, abdominal-pelvic and pulmonary infections. The microbial spectrum and antibiotics sensitivity results could help clinicians to take prompt prophylactic and therapeutic approaches against postoperative infection for PMP patients.
Literature
1.
go back to reference Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.CrossRefPubMed Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.CrossRefPubMed
2.
go back to reference Smeenk RM, Bruin SC, van Velthuysen ML, et al. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45(8):527–75.CrossRefPubMed Smeenk RM, Bruin SC, van Velthuysen ML, et al. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45(8):527–75.CrossRefPubMed
3.
go back to reference Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.CrossRefPubMed Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.CrossRefPubMed
4.
go back to reference Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511–9.CrossRefPubMed Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511–9.CrossRefPubMed
5.
go back to reference Yang R, Su YD, Ma R, et al. Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023;49(1):173–8.CrossRefPubMed Yang R, Su YD, Ma R, et al. Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023;49(1):173–8.CrossRefPubMed
7.
go back to reference Wang H, Wang X, Ju Y, et al. Clinicopathological features and prognosis of pseudomyxoma peritonei. Exp Ther Med. 2014;7(1):185–90.CrossRefPubMed Wang H, Wang X, Ju Y, et al. Clinicopathological features and prognosis of pseudomyxoma peritonei. Exp Ther Med. 2014;7(1):185–90.CrossRefPubMed
8.
go back to reference Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456–62.CrossRefPubMed Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456–62.CrossRefPubMed
9.
go back to reference Guaglio M, Sinukumar S, Kusamura S, et al. Clinical surveillance after macroscopically complete surgery for low-grade appendiceal mucinous neoplasms (LAMN) with or without limited peritoneal spread: long-term results in a prospective Series. Ann Surg Oncol. 2018;25(4):878–84.CrossRefPubMed Guaglio M, Sinukumar S, Kusamura S, et al. Clinical surveillance after macroscopically complete surgery for low-grade appendiceal mucinous neoplasms (LAMN) with or without limited peritoneal spread: long-term results in a prospective Series. Ann Surg Oncol. 2018;25(4):878–84.CrossRefPubMed
10.
go back to reference Ansari N, Chandrakumaran K, Dayal S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035–41.CrossRefPubMed Ansari N, Chandrakumaran K, Dayal S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035–41.CrossRefPubMed
11.
go back to reference Li Y, Xu HB, Peng Z, et al. Expert consensus on cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in the treatment of pseudomyxoma peritonei. Natl Med J Chin. 2019;99(20):1527–35. Li Y, Xu HB, Peng Z, et al. Expert consensus on cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in the treatment of pseudomyxoma peritonei. Natl Med J Chin. 2019;99(20):1527–35.
12.
go back to reference Govaerts K, Lurvink RJ, De Hingh IHJT, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11–35.CrossRefPubMed Govaerts K, Lurvink RJ, De Hingh IHJT, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47(1):11–35.CrossRefPubMed
13.
go back to reference Yang R, Su YD, Liu G, et al. Effect of standardized fluid management on cardiac function after CRS + HIPEC in patients with PMP: a single-center case-control study. Int J Hyperthermia. 2023;40(1):2182749.CrossRefPubMed Yang R, Su YD, Liu G, et al. Effect of standardized fluid management on cardiac function after CRS + HIPEC in patients with PMP: a single-center case-control study. Int J Hyperthermia. 2023;40(1):2182749.CrossRefPubMed
14.
go back to reference Deslauriers N, Olney H, Younan R. Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2011;2(2):61–3.PubMedPubMedCentral Deslauriers N, Olney H, Younan R. Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2011;2(2):61–3.PubMedPubMedCentral
15.
go back to reference Haslinger M, Francescutti V, Attwood K, et al. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med. 2013;2(3):334–42.CrossRefPubMedPubMedCentral Haslinger M, Francescutti V, Attwood K, et al. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med. 2013;2(3):334–42.CrossRefPubMedPubMedCentral
16.
go back to reference Mizumoto A, Canbay E, Hirano M, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012;2012: 836425.CrossRefPubMedPubMedCentral Mizumoto A, Canbay E, Hirano M, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012;2012: 836425.CrossRefPubMedPubMedCentral
17.
go back to reference Viyuela García C, Medina Fernández FJ, Arjona-Sánchez Á, et al. Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC. Surg Oncol. 2020;34:163–7.CrossRefPubMed Viyuela García C, Medina Fernández FJ, Arjona-Sánchez Á, et al. Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC. Surg Oncol. 2020;34:163–7.CrossRefPubMed
18.
go back to reference Valle M, Federici O, Carboni F, et al. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. Eur J Surg Oncol. 2014;40(8):950–6.CrossRefPubMed Valle M, Federici O, Carboni F, et al. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. Eur J Surg Oncol. 2014;40(8):950–6.CrossRefPubMed
19.
go back to reference Smibert OC, Slavin MA, Teh B, et al. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Support Care Cancer. 2020;28(6):2745–52.CrossRefPubMed Smibert OC, Slavin MA, Teh B, et al. Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Support Care Cancer. 2020;28(6):2745–52.CrossRefPubMed
20.
go back to reference Skeie E, Koch AM, Harthug S, et al. A positive association between nutritional risk and the incidence of surgical site infections: a hospital-based register study. PLoS One. 2018;13(5):e0197344.CrossRefPubMedPubMedCentral Skeie E, Koch AM, Harthug S, et al. A positive association between nutritional risk and the incidence of surgical site infections: a hospital-based register study. PLoS One. 2018;13(5):e0197344.CrossRefPubMedPubMedCentral
21.
go back to reference Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRefPubMedPubMedCentral Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRefPubMedPubMedCentral
22.
go back to reference Arslan NC, Sokmen S, Avkan-Oguz V, et al. Infectious complications after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surg Infect (Larchmt). 2017;18(2):157–63.CrossRefPubMed Arslan NC, Sokmen S, Avkan-Oguz V, et al. Infectious complications after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surg Infect (Larchmt). 2017;18(2):157–63.CrossRefPubMed
23.
go back to reference Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1082–7.CrossRefPubMed Canda AE, Sokmen S, Terzi C, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1082–7.CrossRefPubMed
24.
go back to reference Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863–9.CrossRefPubMed Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: Morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863–9.CrossRefPubMed
25.
go back to reference Cardi M, Sibio S, Di Marzo F, et al. Prognostic factors influencing infectious complications after cytoreductive surgery and hipec: Results from a tertiary referral center. Gastroenterol Res Pract. 2019;2019:2824073.CrossRefPubMedPubMedCentral Cardi M, Sibio S, Di Marzo F, et al. Prognostic factors influencing infectious complications after cytoreductive surgery and hipec: Results from a tertiary referral center. Gastroenterol Res Pract. 2019;2019:2824073.CrossRefPubMedPubMedCentral
26.
go back to reference Capone A, Valle M, Proietti F, et al. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol. 2007;96(6):507–13.CrossRefPubMed Capone A, Valle M, Proietti F, et al. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol. 2007;96(6):507–13.CrossRefPubMed
27.
go back to reference Hennessey DB, Burke JP, Ni-Dhonochu T, et al. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg. 2010;252(2):325–9.CrossRefPubMed Hennessey DB, Burke JP, Ni-Dhonochu T, et al. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg. 2010;252(2):325–9.CrossRefPubMed
28.
go back to reference Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15(5):1414–23.CrossRefPubMedPubMedCentral Semino-Mora C, Liu H, McAvoy T, et al. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol. 2008;15(5):1414–23.CrossRefPubMedPubMedCentral
29.
go back to reference Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310.CrossRefPubMed Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310.CrossRefPubMed
30.
go back to reference Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution. Ann Surg. 2010;251(1):101–6.CrossRefPubMed Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution. Ann Surg. 2010;251(1):101–6.CrossRefPubMed
Metadata
Title
Etiological analysis of infection after CRS + HIPEC in patients with PMP
Authors
Rui Yang
Xin Zhao
Yu-Bin Fu
Yu-Lin Lin
Ru Ma
Yan-Dong Su
He-Liang Wu
Xin-Li Liang
Yan Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11404-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine